GSK to pay ‘unprecedented’ $3 billion fraud charge

GlaxoSmithKline will pay $3 billion in fraud charges, the largest of its kind in US history. The charges relate to the off-label promotion of its antidepressants Paxil and Wellbutrin for unapproved u…
Read the full story: InPharm